TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06425926: A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors

Sponsor: Georgiamune Inc · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 117 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$8,207,430

Rescue Site Savings

+$5,419,260

Unlock Full NCT06425926 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06425926 Rescue Dossier →